Willemijn S.M.E. Theelen

Author

Also Known As

Theelen, W. S. M. E., W S M E Theelen, W Theelen, W. S. M. E. Theelen, W. Theelen, W.S. Theelen, W.S.M.E. Theelen, Willemijn S M E Theelen, Willemijn S. M. E. Theelen, Willemijn S. Theelen

111

Publications

6.5K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Radboud University Nijmegen Oncode Institute Radboud University Medical Center The University of Texas MD Anderson Cancer Center

About

Willemijn S.M.E. Theelen is an author at The Netherlands Cancer Institute specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	9	1.1K
2	Immunology	4	4	281
3	Health Sciences	2	2	95
4	Cell Biology	1	1	192
5	Genomic Medicine	1	1	32

Willemijn S.M.E. Theelen

Publications

6.3K

Citations

H-Index

Page 1

	Year	Citations
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn, New England Journal of Medicine	2016	3.2K
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer Willemijn S.M.E. Theelen, Heike Peulen, Ferry Lalezari, JAMA Oncology	2019	935
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials Willemijn S.M.E. Theelen, Dawei Chen, Vivek Verma, The Lancet Respiratory Medicine MedicineRandomised TrialsImmune Checkpoint InhibitorBronchial NeoplasmCancer Treatment	2020	540
Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer Tony Mok, Yi‐Long Wu, M. Ahn, QUT ePrints (Queensland University of Technology)	2017	474
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis Vassiliki A. Papadimitrakopoulou, Tony Mok, Ji‐Youn Han, Annals of Oncology	2020	266
IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer Olga Blomberg, Lorenzo Spagnuolo, Hannah Garner, Cancer Cell Cancer ImmunosurveillanceAutoimmune DiseaseImmunologyImmune Checkpoint InhibitorAutoimmunity	2022	192
Genomic integration of oncogenic HPV and gain of the human telomerase gene <i>TERC</i> at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer A. H. N. Hopman, Willemijn S.M.E. Theelen, PPH Hommelberg, The Journal of Pathology	2006	112
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin, Annals of Oncology Nivolumab Versus DocetaxelMedicinePharmacologyAnti-cancer AgentPhase Iii Study	2023	78
Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath R. de Vries, Mirte Muller, Vincent van der Noort, Annals of Oncology	2019	76
Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: The PEMBRO-RT study. Willemijn S.M.E. Theelen, No Firstname H.Peulen Nki.Nl, Ferry Lalezari, Journal of Clinical Oncology Phase Ii StudyImmunotherapyTreatment VerificationRadiation MedicineClinical Radiation Oncology	2018	63

Page 1